Acrivon stockholders OK 3M share equity plan increase; elect Tomsicek, Baum

Acrivon Therapeutics, Inc.

Share reserve increased by 3M shares to 8,606,723; annual 5% auto-increase through 2032 approved.
Michael Tomsicek and Charles Baum elected Class I directors until 2029 annual meeting.
PricewaterhouseCoopers ratified as independent auditor for fiscal year 2026.
Proposals passed with >65% of votes cast; quorum 73.21% of outstanding shares.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Acrivon Therapeutics, Inc. shareholders approved Approval of the Amendment and Restatement of the Company's 2022 Equity Incentive Plan.

Proposal: equity plan
Outcome: passed

Exact text from the filing

Votes were cast as follows: For Against Abstain Broker Non-Votes 20,546,400 3,757,400 104,757 6,928,436

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Acrivon Therapeutics, Inc. shareholders approved Election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors.

Proposal: director election
Outcome: passed

Exact text from the filing

Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 24,020,408 1,229,385 6,087,200 Charles Baum, M.D., Ph.D. 23,657,074 1,592,719 6,087,200

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm.

Proposal: auditor ratification
Outcome: passed

Exact text from the filing

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-274410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.